Blinatumomab for the treatment of acute lymphoblastic leukemia

Discussion and conclusions Blinatumomab represents a significant addition to the treatment options for ALL, but it is not without its limitations, of which are its short-half life, necessitating long-term CIVI, and the eventual emergence of CD19-negative clones. Continual development of the agent involves assessing its role in the frontline setting and in combination with chemotherapy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research